Legend Biotech Corporation
LEGN
Rang in Aktien
#4443
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Aktienkurs
$19.00
Marktkapitalisierung
$3.51B
Veränderung (1 Tag)
1.88%
Veränderung (1 Jahr)
-42.27%
Land
US
Handel Legend Biotech Corporation (LEGN)
Kategorie
Healthcare
Gewinn für Legend Biotech Corporation (LEGN)
Gewinn im Jun 2026 TTM: $-56.27M
Laut den aktuellen Finanzberichten von Legend Biotech Corporation betragen die aktuellen Gewinne des Unternehmens $-56.27M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-520.12M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-445.72M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Legend Biotech Corporation von 2017 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-56.27M | -64.41% |
| 2024 | $-158.13M | -69.60% |
| 2023 | $-520.12M | 16.69% |
| 2022 | $-445.72M | 9.46% |
| 2021 | $-407.20M | 32.08% |
| 2020 | $-308.29M | 142.14% |
| 2019 | $-127.32M | 7,778.65% |
| 2018 | $-1.62M | -111.68% |
| 2017 | $13.84M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -9,473.93% |
US
|
|
| $-3.09B | 5,385.85% |
US
|
|
| $-4.02B | 7,037.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,566.47% |
NL
|
